Universal CAR-T Cells therapy(Peking University Third Hospital)

N/A

Report date: 2025/05/14 15:50:08

Base Information

Drug NameUniversal CAR-T Cells therapy(Peking University Third Hospital)
Drug Alias NameUWD-CD19
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy > Universal CAR-TCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionB-lymphocyte antigen CD19 modulatorsT lymphocyte replacements
TargetsB-lymphocyte antigen CD19
Therapy Area/IndicationsScleroderma, SystemicLupus Erythematosus, SystemicAnti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesThe Third Affiliated Hospital Of Beijing University
China Registration ClassN/A

Develop Information

Active CompaniesThe Third Affiliated Hospital Of Beijing University
Inactive CompaniesN/A
Active IndicationsScleroderma, SystemicLupus Erythematosus, SystemicAnti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis +[5] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A